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R. Kempsford et al.S12salmeterol with fewer adverse events occurring with the HFA compared with the CFC
formulation. These data indicate that the salmeterol HFA MDI would not be
associated with a significantly different pharmacodynamic, safety and tolerability
profile compared with the salmeterol CFC MDI.
& 2004 Elsevier Ltd. All rights reserved.Introduction
Pressurised metered-dose inhalers (MDIs) are the
most widely used system of inhaled drug delivery
for the treatment of respiratory diseases, such as
asthma and chronic obstructive pulmonary disease
(COPD).1,2 Until recently, the non-toxic, inert and
non-flammable nature of chlorofluorocarbons
(CFCs) made them excellent candidates for use as
medicinal aerosol propellants in MDIs. However,
due to their potential to damage the ozone layer,
CFCs are being phased out worldwide in accordance
with the Montreal Protocol 1987.3,4 In response to
this directive, alternative CFC-free propellants are
being developed for use in medical devices.5 The
non-toxic, non-flammable, odour free and chemi-
cally stable hydrofluoroalkanes (HFAs) are consid-
ered appropriate replacements for CFCs.6–12
Metered-dose inhalers containing HFA-134a as the
propellant have become widely available and are
included in several medicinal products, such as
salbutamol,13–15 fluticasone propionate16 and be-
clomethasone dipropionate.17 An HFA-134a-con-
taining MDI has now been developed for the long-
acting beta2 agonist, salmeterol (Serevent
TM),
which is currently available both as a dry powder
(Accuhaler/Diskus, Diskhaler) and as an MDI for-
mulated with CFC propellants 11 and 12.
The in vitro pharmaceutical performance of the
salmeterol HFA MDI has been shown to be compar-
able to the marketed CFC containing MDI.18
However, although in vitro testing can be used to
make a comparison between MDI formulations and
devices, quality control, and to derive estimates of
the likely lung deposition,19 clinical studies are
ultimately required to confirm that the HFA- and
CFC-containing MDIs are similar in respect of their
pharmacodynamic, pharmacokinetic, safety, toler-
ability and efficacy profiles. Salmeterol at ther-
apeutic doses produces low plasma concentrations
that are detectable for only a short period
immediately after administration. This makes a
full characterisation of the salmeterol pharmaco-
kinetic profile at therapeutic doses difficult.20 In
addition, these doses of salmeterol are associated
with minimal systemic pharmacodynamic effects.
Consequently, in this study, supratherapeutic doses
of salmeterol (150 and 300 mg) were also studied toproduce greater systemic salmeterol exposure in
order to permit a comparison of the pharmacoki-
netic and pharmacodynamic profiles of salmeterol
delivered by the HFA and CFC propellant MDIs.
The purpose of this study was to determine the
effect of reformulation of salmeterol in HFA-134a
on the systemic pharmacodynamics and pharmaco-
kinetics of salmeterol in man. The results of this
study, together with data for in vitro performance18
and clinical efficacy,21 can be used to demonstrate
the suitability of the salmeterol HFA MDI as a
replacement for the existing CFC containing MDI.Methods
Study design
This was a single-centre, randomised, double-
blind, placebo-controlled, five-way crossover study
designed to determine whether the systemic
pharmacodynamic responses to salmeterol deliv-
ered from the HFA and CFC MDIs are equivalent in
healthy male subjects. A local independent ethics
committee reviewed the study protocol and the
study was conducted according to Good Clinical
Practice and the 1996 version of the Declaration of
Helsinki.
Subjects underwent a screening visit to test their
eligibility to participate in the study; screening also
included instruction and practise with the MDI
device used in the study. After screening, subjects
were randomised into one of three groups of ten
subjects to receive study drug in a random order on
five separate study days (four active treatments
and one of placebo); each study day was separated
by at least 7 days. On study days, subjects fasted
from midnight on the day prior to dosing until 4 h
after dosing. To ensure that treatment blind was
maintained, subjects made a total of 12 inhalations
from three inhalers with active doses being
dispensed as salmeterol 25 mg per actuation where
appropriate. Dosing was completed within 3min.
Subjects underwent blood sampling and safety
evaluations for approximately 12 h after dosing. A
follow-up visit was performed approximately 7 days
after the last treatment.
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Subjects were healthy male volunteers aged 18–50
years who were free from clinically significant
illness or disease as determined by their medical
history (including family history), physical exam-
ination, and laboratory tests. Subjects were non-
smokers (at least 12 months) with a body mass
index 19–29 kg/m2. The main study exclusion
criteria were: a history or current evidence of
chronic bronchitis, emphysema, asthma, or any
other lung disease of clinical significance; a recent
upper or lower respiratory tract infection or
symptoms; current or recent use of any prescription
or over-the-counter medication; clinically signifi-
cant abnormal 12-lead ECG values at the screening
visit; or a history of drug or alcohol abuse.
Pharmacodynamic assessments
On each study day, supine blood pressure, heart
rate and 12-lead ECG were measured pre-dose and
15, 30, 45min, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 h post-
dose. Blood samples (5mL) for serum potassium
were collected into Serum Separator Tubes (BD
Vacutainer SST) at pre-dose and 0.5, 1, 2, 4, 8 and
12 h post-dose. Samples were allowed to coagulate
and centrifuged for 15min at 1500 g at room
temperature. Blood samples (5mL) for glucose
were collected into fluoride-oxalate tubes at pre-
dose and 0.5, 1, 2, and 4 h post-dose.
Pharmacokinetic assessments
Blood samples (approximately 1.5mL each) for the
determination of salmeterol plasma concentrations
were collected pre-dose and at the nominal times
of 5, 10, 20, 30 and 45min and 1, 1.5, 2, 3, 4, 5, 6,
8, 10 and 12 h post-dosing in each period.
Blood samples were collected into lithium hepar-
in tubes and centrifuged, within 1 h of collection,
at 1500 g for 10min at 4 1C. Supernatant plasma
(approximately 0.7mL) was transferred to 3.6mL
Nunc tubes and stored at 20 1C until analysis.
Plasma salmeterol was measured by a validated
method using liquid chromatography-tandem mass
spectrometry following solid phase extraction.22
The calibration threshold range for the assay was
25–1000 pg/mL, with an inter-assay precision (%CV)
of 13.4%.
Pharmacokinetic parameters for salmeterol were
determined using non-compartmental methods
(WinNonlin Pro, ver 4.0.1; Scientific Consulting
Inc., Cary, NC, USA). Maximum plasma concentra-
tion (Cmax), area under the plasma concentration–time curve from zero to the last measurable
concentration (AUClast) and time to maximum
plasma concentration (tmax) were recorded where
there was a sufficient number of plasma concentra-
tion data points to provide evaluable data. Values
of Cmax and tmax were taken from raw data and
those for AUClast were calculated using a combina-
tion of linear and logarithmic trapezoidal methods.Safety assessments
Adverse events were recorded throughout the study
following spontaneous reporting and indirect in-
vestigator questioning when patients attended the
clinic. Clinical chemistry and haematology para-
meters were assessed at screening and at the post-
treatment follow-up visit. Vital signs (systolic and
diastolic blood pressure and heart rate measure-
ments) and readings from a full 12-lead ECG (QT
interval, QTc interval (using Bazett’s correction),
PR interval and QRS interval) were measured at
screening, at intervals throughout study days and at
follow up.Statistical analysis
Selection of the study sample size was based on
both logistical and statistical considerations. Thirty
subjects were to be studied so that at least 24
subjects would complete the clinical phase of the
study. Data from a previous study with salmeterol
indicated a within subject standard deviation after
dosing with salmeterol 400 mg HFA MDI of 6.5 bpm
for heart rate.23 With 24 subjects and assuming no
difference between the two treatments (salmeter-
ol 50 mg HFA MDI and salmeterol 50 mg CFC MDI), it
was estimated that the study would have a greater
than 90% power to confirm the equivalence of the
two treatments with respect to maximum heart
rate and minimum potassium level after dosing. It
was also estimated that a cohort this size would
allow equivalence to be detected if the 95%
confidence intervals for the mean difference
between the two treatments was contained within
710 bpm for heart rate and 70.33mmol/L for
serum potassium concentration.
The primary pharmacodynamic comparisons of
interest were the 95% confidence intervals for the
differences in the means for salmeterol 50 mg HFA
and salmeterol 50 mg CFC MDI for both maximum
heart rate (0–12 h post-dose) and minimum serum
potassium level (0–4 h post-dose). The comparisons
were repeated for minimum diastolic blood pres-
sure, maximum systolic blood pressure and max-
imum QTc interval for over 12 h post-dose and
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All primary and secondary measures (including the
primary comparison measures; maximum heart rate
and minimum serum potassium level) were re-
peated for salmeterol 150 mg HFA versus salmeterol
150 mg CFC MDI, salmeterol 300 mg HFA versus
salmeterol 300 mg CFC MDI, and active treatments
versus placebo at each dose level (50, 150 and
300 mg).
For the pharmacokinetic endpoints AUC(0t),
Cmax, and tmax the treatment comparisons of
interest were: salmeterol 50 mg HFA MDI versus
salmeterol 50 mg CFC MDI, salmeterol 150 mg HFA
MDI versus salmeterol 150 mg CFC MDI, and salme-
terol 300 mg HFA MDI versus salmeterol 300 mg
CFC MDI.
Estimates of parameters are presented as mean
(SD) (taken from summary statistics), and differ-
ences between parameters are presented as the
difference between the least-square means (LS
means) (taken from the analysis) unless otherwise
stated. Normality was investigated for all para-
meters using the PROC UNIVARIATE procedure in
SAS (SAS ver 8.2; SAS Institute, Carey, NC, USA).
Mixed effects models were fitted with treatment
group and period as fixed effects and subject as a
random effect for all pharmacodynamic analyses.
Treatment differences were calculated by the
difference between the LS means and were
determined by their 95% confidence intervals using
a pooled estimate of variance.
For pharmacokinetic data, statistical analyses
were performed after log-transformation of the
data. A mixed effects model was fitted with fixed
effects for period and active treatment group, and
random effects for subject. Each active treatment
was compared at the same dose level. Treatment
ratios were calculated by taking the anti-log of the
difference between the LS means and were
determined by their 95% confidence intervals using
a pooled estimate of variance.
Dose effects for maximum heart rate (0–12 h
post-dose) and minimum serum potassium level
(0–4 h post-dose) were investigated by fitting a
mixed model with subject as a random effect and
dose, treatment, period and dose x treatment as
fixed effects. Estimates of dose differences and
90% confidence intervals for the difference were
calculated.
The Kenward and Rodger method for approximat-
ing the denominator degrees of freedom and
correcting for bias in the estimated variance–cov-
ariance of the fixed effects was used for all
analyses. For maximum heart rate (0–12 h post-
dose) and minimum serum potassium level (0–4 h
post-dose), confidence limits of 710 bpm and70.33mmol/L for differences in the LS means
were considered to be statistically equivalent.Results
Subject disposition and baseline
characteristics
Thirty healthy male subjects were randomised to
one of three study groups. Each subject received
four active treatments comprising of two dose
levels of salmeterol (50 and 150, 50 and 300 or 150
and 300 mg) from both the CFC and HFA MDIs and
placebo HFA MDI. Twenty-six subjects completed
the study. Four subjects were discontinued prema-
turely, three for adverse events (inter-current
illness unrelated to study drug) and one for a
protocol violation. No subject was excluded from
the analysis due to non-compliance with the study
protocol.
Pharmacodynamic results
In the case of salmeterol 50 mg, both the HFA and
CFC MDIs demonstrated pharmacodynamic equiva-
lence with placebo according to the pre-defined
criterion for clinical equivalence—that the 95% CIs
for the difference in maximum heart rate fell
within the range 10 to +10 bpm. Summaries of
maximum heart rate (0–12 h post-dose) showed
mean values following salmeterol 50 mg HFA to be
69.7 bpm and after salmeterol 50 mg CFC, 73.7 bpm
(Table 1). Analysis of the difference between
means (95% CI) was 4.06 (8.12, 0.01) bpm
(Table 1).
Mean minimum serum potassium concentration
(04h post-dose) following salmeterol 50mg HFAwas
3.90mmol/L and that after salmeterol 50mg CFC was
3.81mmol/L. The difference in the means (95% CI)
for salmeterol 50mg HFA and salmeterol 50mg CFC
was 0.08 (0.02, 0.18) mmol/L (Table 1). The 95% CI
values for the difference in minimum serum potas-
sium fell within the range0.33 to 0.33mmol/L, the
range specified in the study rationale as representing
clinical equivalence, indicating that the effect of
salmeterol on serum potassium was equivalent for
the two MDI formulations.
At doses above the therapeutic dose, salmeterol
HFA (150–300 mg) produced dose-related beta-ago-
nist pharmacodynamic effects, demonstrating con-
sistent increases in heart rate compared with
placebo (Fig. 1). Doses were equivalent for each
MDI formulation with respect to maximum heart
rate (0–12 h), except for the 150 mg dose level
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Table 1 Mean maximum heart rate (0–12 h post-dose) and minimum serum potassium (0–4 h post-dose) and
treatment differences after administration of salmeterol 50–300 mg by HFA and CFC MDIs in healthy subjects.
Comparison of interest Least-squares mean values Treatment difference
Test treatment
(bpm)
Reference
treatment (bpm)
Difference 95% CI
Maximum heart rate (0–12 h) (bpm)
HFA 50 mg versus CFC 50 mg 69.68 73.74 4.06 8.12, 0.01
HFA 150 mg versus CFC 150 mg 74.80 82.23 7.43 11.69, 3.18
HFA 300 mg versus CFC 300 mg 86.68 88.37 1.69 5.79, 2.41
HFA 50 mg versus Placebo 69.68 68.11 1.56 2.19, 5.31
HFA 150 mg versus Placebo 74.80 68.11 6.68 2.84, 10.52
HFA 300 mg versus Placebo 86.68 68.11 18.57 14.72, 22.42
CFC 50 mg versus Placebo 73.74 68.11 5.62 1.80, 9.45
CFC 150 mg versus Placebo 82.23 68.11 14.12 10.13, 18.11
CFC 300 mg versus Placebo 88.37 68.11 20.26 16.41, 24.10
Minimum serum potassium (0–4 h) (mmol/L)
HFA 50 mg versus CFC 50 mg 3.90 3.81 0.08 0.02, 0.18
HFA 150 mg versus CFC 150 mg 3.75 3.52 0.23 0.13, 0.34
HFA 300 mg versus CFC 300 mg 3.48 3.33 0.15 0.05, 0.26
HFA 50 mg versus Placebo 3.90 3.94 0.04 0.14, 0.05
HFA 150 mg versus Placebo 3.75 3.94 0.18 0.28, 0.09
HFA 300 mg versus Placebo 3.48 3.94 0.45 0.55, 0.36
CFC 50 mg versus Placebo 3.81 3.94 0.12 0.22, 0.03
CFC 150 mg versus Placebo 3.52 3.94 0.42 0.52, 0.32
CFC 300 mg versus Placebo 3.33 3.94 0.61 0.70, 0.51
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Figure 1 Mean (SD) maximum heart rate (0–12 h post-
dose) following administration of salmeterol 50–300 mg by
HFA and CFC MDIs in healthy subjects.
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Figure 2 Mean (SD) minimum serum potassium (0–4 h
post-dose) following administration of salmeterol
50–300 mg by HFA and CFC MDIs in healthy subjects.
CFC versus non-CFC propellant equivalence of salmeterol S15where the 95% CI (11.69, 3.18) for the differ-
ence fell outside the 10 to +10 bpm range
(Table 1).The increases in heart rate following salmeterol
CFC were consistently greater than those following
salmeterol HFA, irrespective of dose (Table 1).
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R. Kempsford et al.S16Analysis of change in heart rate with dose showed
them to be dose proportional with mean (90% CI)
increases in heart rate of 0.059 (0.0567, 0.0850)
and 0.071 (0.0446, 0.0734) bpm per unit dose (1 mg)
for salmeterol CFC and salmeterol HFA, respec-
tively.
Both salmeterol HFA and salmeterol CFC
(150–300 mg) produced dose-related decreases in
minimum serum potassium concentration (0–4 h
post-dose) compared with placebo (Fig. 2). De-
creases appeared greater with the CFC formula-
tion. Overall, the MDI formulations appeared to be
equivalent with respect to the effects on minimum
serum potassium levels (0–4 h post-dose; Table 1).
Analysis of change in serum potassium with dose
showed them to be dose proportional with mean
(90% CI) decreases in concentration of 0.0019
(0.0023, 0.0016) and 0.0017 (0.0020,
0.0013)mmol/L per unit dose (1 mg) for salmeter-
ol CFC and salmeterol HFA, respectively.0
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Figure 3 Median salmeterol plasma concentrations fol-
lowing administration of salmeterol 300 mg by HFA and
CFC MDIs in healthy subjects (0–4 h post-dose data only).Pharmacokinetic results
Dose-related increases in salmeterol plasma con-
centrations were observed at all time-points for all
salmeterol HFA treatments. Salmeterol plasma
concentration–time profiles following administra-
tion of salmeterol HFA were similar in shape to the
salmeterol CFC treatment profiles with a multiple
exponential decline. Mean peak salmeterol plasma
concentrations were consistently lower following
administration of salmeterol HFA than those
obtained following the same dose of salmeterol
CFC (Table 2). At the therapeutic dose (50 mg),
salmeterol doses were only measurable up to 5 h
post-dose. At higher doses of 150–300 mg, salmeter-
ol was measurable in most samples for the full 12 hTable 2 Mean (95% CI) plasma salmeterol pharmacokine
50–300 mg by HFA and CFC MDIs in healthy subjects.
Parameter Dose
50 mg
CFC
Cmax (pg/mL) 541.1 (136.5, 2145.3)
tmax
 (h) 0.083 [0.083, 0.100]
AUC(0t) (pg.h/mL) 278.6 (39.4, 1972.0)
HFA
Cmax (pg/mL) 224.0 (71.0, 706.7)
tmax
 (h) 0.083 [0.083, 0.083]
AUC(0t) (pg.h/mL) 80.6 (14.3, 453.1)
Data provided as median [range].sampling period, although only the 300 mg dose
level gave a full pharmacokinetic profile. The early
(0–4 h post-dose) salmeterol concentration–time
profiles highlighting differences between the med-
ian concentrations with the two MDI formulations
at the 300 mg salmeterol dose is shown in Fig. 3.
The type of propellant had no apparent effect on
the time taken to attain maximum plasma concen-
trations of salmeterol as tmax had generally been
reached by the first sampling time (5min.) follow-
ing administration of salmeterol HFA and salmeter-
ol CFC at all dose levels (Table 2). It is unlikely that
these data represent the true Cmax or tmax values as
this would require the ability to detect rising
plasma concentrations before, as well as falling
concentrations after, the Cmax values. Taking ear-
lier plasma samples was not practical given the
multiple inhalation dosing schedule.tic parameters following administration of salmeterol
150 mg 300 mg
1286.6 (269.7, 6136.3) 2005.5 (735.4, 5469.2)
0.083 [0.083, 0.167] 0.083 [0.083, 0.167]
1233.3 (278.0, 5472.7) 2254.5 (984.3, 5163.6)
700.8 (220.7, 2225.5) 1482.0 (453.4, 4844.7)
0.083 [0.083, 0.167] 0.083 [0.083, 0.167]
558.9 (134.5, 2339.0) 1612.7 (618.9, 4202.1)
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Table 3 Comparison between salmeterol AUC(0t) and Cmax values after administration of salmeterol 50–300 mg
by HFA and CFC MDIs in healthy subjects.
Comparison Parameter Ratio 95% CI
HFA 50 mg/CFC 50 mg Cmax (pg/mL) 0.40 (0.31, 0.52)
AUC(0t) (pg.h/mL) 0.28 (0.19, 0.39)
HFA 150 mg/CFC 150 mg Cmax (pg/mL) 0.56 (0.43, 0.74)
AUC(0t) (pg.h/mL) 0.46 (0.32, 0.67)
HFA 300 mg/CFC 300 mg Cmax (pg/mL) 0.73 (0.56, 0.94)
AUC(0t) (pg.h/mL) 0.70 (0.49, 1.00)
CFC versus non-CFC propellant equivalence of salmeterol S17Table 3 shows that estimates of the salmeterol
Cmax following administration of salmeterol HFA
were, on average, 60% lower, 44% lower and 27%
lower than following administration of salmeterol
CFC at 50, 150 and 300 mg, respectively. Estimates
of the salmeterol AUC(0t) following administration
of salmeterol HFA were, on average, 72% lower, 54%
lower and 30% lower than following administration
via salmeterol CFC at 50, 150 and 300 mg, respec-
tively. The systemic exposure to salmeterol, based
on AUC(0t) and Cmax, was therefore lower follow-
ing administration of salmeterol HFA than following
salmeterol CFC, with 95% CIs consistently less than
unity (Table 3). For AUC(0t) at the high dose level,
the 95% CI only just included unity, suggesting that
systemic exposure to salmeterol was not markedly
different between administration via salmeterol
HFA and salmeterol CFC.
Safety results
The adverse events profile with both MDI formula-
tions at therapeutic doses (50 mg) was similar to
that of placebo HFA. There were no unexpected
adverse events recorded with the salmeterol HFA
formulation and no serious adverse events were
reported during the study. The incidence of adverse
events for both MDI formulations appeared to be
dose-dependent within each formulation and, at
higher doses, were typical for a high dose beta
agonist. The most frequently reported events were
headache, tremors and palpitations. However,
adverse events, specifically tremors at the highest
dose, were more frequently reported after the CFC
MDI formulation.Discussion
The present study demonstrates that salmeterol
delivered via the HFA-propelled MDI is not asso-ciated with a higher systemic exposure or increased
systemic pharmacodynamic effects compared with
salmeterol delivered by the CFC-propelled MDI.
These data, together with the in vitro pharmaceu-
tical performance18 and demonstration of non-
inferiority for clinical efficacy in both adult and
paediatric asthma patients,21 suggest that the
salmeterol HFA MDI represents an acceptable
replacement for the salmeterol CFC MDI. At the
therapeutic dose of salmeterol (50 mg), the sys-
temic pharmacodynamic effects (heart rate, serum
potassium, plasma glucose, QTc interval or blood
pressure) of salmeterol via HFA and CFC MDIs were
equivalent or comparable. At higher doses the
salmeterol HFA MDI produced dose-related beta-
agonist pharmacodynamic effects. However, these
were consistently less than those produced by the
salmeterol CFC MDI at each dose level. These
differences appeared to be related to the lower
systemic exposure to salmeterol for the HFA MDI.
The salmeterol HFA MDI was safe and well-tolerated
with few adverse events reported. At therapeutic
doses the number of adverse events reported was
similar to placebo. At supratherapeutic doses the
adverse events were typical for high dose salme-
terol and fewer were reported with the salmeterol
HFA MDI than with the salmeterol CFC MDI.
Both salmeterol HFA and salmeterol CFC
(150–300 mg) confirmed previously observed beta-
agonist pharmacodynamic effects on heart rate,
derived QTc interval values, minimum serum
potassium concentration, maximum systolic blood
pressure and maximum plasma glucose concentra-
tion.24 In all cases, the effects were significantly
greater with the salmeterol CFC than with the HFA
formulation.
At the salmeterol 50 mg therapeutic dose, the
small but statistically significant difference in mean
maximum heart rate (0–12 h post-dose) between
the salmeterol HFA and CFC devices was not
attributable to an effect of the salmeterol HFA
MDI on heart rate, which did not differ from
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R. Kempsford et al.S18placebo. Despite this small difference, equivalence
between the two MDIs was considered to be
achieved as the 95% CIs for both the differences
in the means for maximum heart rate (0–12 h post-
dose) and minimum serum potassium (0–4 h post-
dose) fell within the predefined limits of 710 bpm
and70.33mmol/L, respectively. The actual differ-
ences in mean values were relatively negligible
(4.1 bpm and 0.08mmol/L, respectively), indicat-
ing that the systemic pharmacodynamic effects of a
therapeutic dose of salmeterol 50 mg delivered
from the HFA MDI would not be expected to be
clinically significantly different from those pro-
duced by the marketed CFC MDI.
A secondary aim of this study was to compare the
pharmacokinetics of salmeterol delivered by the
HFA and CFC MDIs in healthy subjects. The findings
of this study indicate that systemic exposure to
salmeterol was lower following administration via
the salmeterol HFA MDI than via the salmeterol
propellant 11/12 MDI, as the 95% CIs for the
AUC(0t) and Cmax ratios were consistently less than
unity. This lower systemic exposure to salmeterol
was consistent with the lower systemic pharmaco-
dynamic effects produced by salmeterol HFA MDI.
Salmeterol plasma concentration profiles follow-
ing administration of therapeutic doses of salme-
terol from CFC MDIs containing either salmeterol
alone or in combination with fluticasone propionate
are characterised by a rapid tmax followed by a
rapid decline to low concentrations.20 At the lower
salmeterol doses used in the present study, plasma
salmeterol concentrations declined rapidly to be-
low the limit of detection for the assay. As a result,
dose proportionality could not be determined
reliably. In contrast, full plasma salmeterol phar-
macokinetic profiles for the highest dose of
salmeterol (300 mg) produced reliable estimates
for the salmeterol pharmacokinetic parameters.
Although the HFA: CFC ratio for AUC(0t) at the
300 mg salmeterol dose only just included unity,
comparing all the pharmacokinetic data at the
different dose levels suggests that systemic ex-
posure to salmeterol was lower following adminis-
tration of the salmeterol HFA MDI compared with
the salmeterol CFC MDI.
The precise reasons for the lower systemic
salmeterol exposure produced by the HFA MDI are
not known. The HFA-CFC difference was predomi-
nantly seen in the early Cmax where absorption is
attributable to the inhaled fraction with little
contribution from the oral swallowed fraction
which produces a much later Cmax.
20,25 The
salmeterol CFC and HFA MDI formulations were
both suspensions with a similar overall fine particle
mass.18 However, the complexity of the interactionbetween an emitted MDI aerosol plume and the
airways cannot be defined using simple measures of
device performance such as fine particle mass.19
Other formulation variables including plume velo-
city, vapor pressure, the presence of surfactants
and electrostatic charges can all influence MDI
performance and drug deposition.19 Differences in
these parameters could contribute to an altered
deposition pattern resulting in the small pharma-
cokinetic effect seen. However, for topically active
inhaled drugs such as salmeterol these minor
differences in systemic exposure appear not to be
clinically significant as there were no differences in
either the efficacy or safety of CFC and HFA
salmeterol in children or adults.21
Whatever the underlying reason(s) for the lower
systemic exposure seen with the salmeterol HFA
MDI in this study, at the therapeutic dose the HFA
MDI was associated with similar or less systemic
effects and similar efficacy21 to the CFC MDI. This is
comparable to the findings with a number of other
compounds, including salbutamol,26 fluticasone
propionate27 and formoterol28 where CFC to HFA
transition resulted in little or no pharmacokinetic
differences and dosage adjustments were not
required. In contrast, development of solution
HFA MDIs, for example beclomethasone dipropio-
nate, was associated with increased fine particle
mass and lung deposition resulting in greater
systemic exposure29,30 and a worsened therapeutic
index requiring dose adjustment.31
The results of the study indicate that salmeterol
50–300 mg delivered from the salmeterol HFA MDI is
safe and well-tolerated. High dose salmeterol
delivered from the HFA MDI was associated with a
similar or lower incidence of adverse events
compared with salmeterol delivered from the CFC
MDI. The type of adverse events recorded with the
salmeterol HFA MDI were no different from the
salmeterol CFC MDI and were typical of high dose
salmeterol and other long-acting beta agonists.
These results indicate delivery of salmeterol via the
HFA MDI was not associated with a significant
alteration in the adverse event profile compared
with the salmeterol CFC MDI.Conclusion
In the present study, the systemic pharmacody-
namic effects of the salmeterol HFA MDI and
salmeterol CFC MDI were equivalent at a therapeu-
tic salmeterol dose of 50 mg. At higher, suprather-
apeutic doses the salmeterol HFA MDI produced
dose-related beta-agonist pharmacodynamic
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by the salmeterol CFC MDI and were consistent with
a lower salmeterol systemic exposure. These data
indicate that the salmeterol HFA MDI would not be
associated with a significantly different pharmaco-
dynamic, safety and tolerability profile compared
with the salmeterol CFC MDI.Acknowledgements
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